• Home
  • » 
  • Reports
  • » 
  • Bispecific Antibody Therapeutics Market,...

Bispecific Antibodies

Bispecific Antibody Therapeutics Market, 2013 - 2023

  • Lowest Price Guaranteed From USD 1,699

  • Published
    September 2013

  • Pages
    166

  • View Count
    6261

  • Buy Now

Example Insights

An updated edition is available at the following link 

View 4th edition

  1. The analysis of content presented on informal (100 patient blogs and over 3,000 social media posts) and formal (180 scientific articles) literary sources, and the opinions expressed by industry experts confirm the existence of a significant unmet need within the chronic kidney disease market. Some of the unaddressed concerns suggested across multiple portals include improved therapeutic strategies, better management of comorbidities, lack of awareness related to the conditions leading to chronic kidney disease, high economic burden, unavailability of dialysis centersand poor quality of life.
  2. Presently, over 160 product candidates are being evaluated across various stages of development for the management / treatment of chronic kidney disease. Of these, 24% are in the preclinical or discovery phase. Amongst the drugs that are under clinical development, 33 are in phase III / pre-registration, 47 in phase II, and 22 in phase I and phase I/II trials. Interestingly, since 2012, 22 product candidates have been commercialized; examples include JYNARQUE® (2018), Parsabiv™ (2017), RAYALDEE® (2016) and VELTASSA® (2015).  
  3. Majority of novel drug candidates (close to 70%) are disease modifying agents, while nearly 30% designed to provide symptomatic relief only. It is worth highlighting that 75% of pipeline candidates are small molecules, and the rest are biologics. Further, most are being developed as monotherapies (close to 75%), whereas nearly 25% are currently being investigated as combination therapies.
  4. The market landscape is characterized by the presence of large (31), mid-sized (33) and small-sized companies (47). Examples of prominent large companies engaged in this domain include (in alphabetical order, no selection criteria) Amgen, Asahi Kasei Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Novartis Pharmaceuticals, Pfizer and Sanofi. The growing unmet need within this domain has spurred the establishment of many start-ups / small-sized companies in the recent years; examples include (in alphabetical order, no selection criteria) Algomedix, Angion Biomedica, Anthera Pharmaceuticals, Apellis Pharmaceuticals, Complexa, Ember Therapeutics, Genkyotex, Goldfinch Bio, inRegen, Kezar Life Sciences, Lanthio Pharma, Orbis Biosciences, Redx pharma, Sanifit and Serodus.
  5. Stakeholders in the industry have forged several strategic partnerships in the recent past; we observed that 28% of the agreements that were signed between 2015 and 2018 were related to research and development. These were followed by development and commercialization agreements (23%), licensing agreements (22%), commercialization agreements (15%), acquisitions (5%), mergers (5%), and manufacturing agreements (2%). Examples of recently inked deals include collaborations between Novo Nordisk and Evotec (August 2018), Resverlogix and Medison Pharma (January 2018), and AstraZeneca and Ionis Pharmaceuticals (February 2018).
  6. Drug development initiatives by start-ups have received financial support in terms of venture funding and research grants. In fact, more than USD 4.1 billion, across 118 instances of grants, venture capital rounds and public offerings, has been invested in these companies since 2010. Across all the funding rounds, the most active investors include (in terms of participation in funding rounds) Omega Funds, Flagship Pioneering, Polaris Partners, venBio Select, Oxford Finance, OrbiMed Advisors, Morningside Group, Limulus Venture Partners, Cormorant Asset Management, AJU IB Investment and Sibling Capital.
  7. Several prominent scientists (over 100) have made significant contributions in advancing the clinical development efforts, and therefore, have emerged as key opinion leaders in this field. Examples of prominent universities and hospitals that have been engaged in conducting breakthrough research in this domain include (in alphabetical order, no selection criteria) Icahn School of Medicine, UC San Diego School of Medicine, University of Michigan, University of Oxford and Vanderbilt University Medical Center.   

Report Description

Antibody based therapeutics are the fastest growing segment of the drugs and biologics market. There are 30 approved antibody based therapeutics available in the US and European markets since the launch of first anti-CD3 antibody, Orthoclone Okt3, in 1986.

A bispecific antibody is a second generation immunotherapy, an upgraded version of monoclonal antibody improved in structure and functionality. The conjugated artificial antibodies are formed by physically putting together two monoclonal antibodies (or parts of) which have different binding specificities. This results in a combination antibody that has simultaneous functional binding affinities to two or three different epitopes. The combination may have additive and sometimes even a synergistic effect in combating a disease.

With the EMA approval for Removab in 2009, a great deal of interest has been generated in the bispecific antibody market. The pipeline is rich and diverse, with drugs being developed for both oncological and non-oncological indications. The industry has drugs in phase I and phase II of clinical trials but currently lacks drugs in phase III.

The Bispecific Antibody Therapeutics Market, 2013-2023 report extensively studies the current and upcoming market of the bispecific antibodies for therapeutic use. This new class of antibody based therapeutics are likely to help target and combat multifactorial diseases through their potential to bind two antigens simultaneously.

 

Scope of the Report

The report covers bispecific antibody drugs currently available in the market as well as in various stages of clinical trials. It highlights various companies which are active in the market and discusses, in detail, the technologies which form the basis of many of the pipeline drugs.

Expecting more FDA and EMA approvals of bispecific antibodies in the coming years, one of the key objectives of this report is to forecast the size of this market over the course of next ten years. This is done by analysing:

  • Molecules in pipeline and drugs approved for marketing across various geographical regions
  • Research programs, focused on bispecific antibody therapeutics, of global pharmaceutical companies and recently established start-ups
  • Technologies to produce bispecific antibodies
  • Likely adoption rate of the new drugs, some of which are expected to be used for lifecycle management of existing drugs

The report provides short-mid term and long term market forecasts for the period 2013 - 2018 and 2018 - 2023, respectively. We have discussed, in detail, the key drivers behind the growth of this market. The research, analysis and insights presented in this report include the sales of eight marketed and pipeline bispecific antibodies. Owing to niche nature of the market, with most products in the pipeline, we provide three scenarios for our market forecast to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of market evolution. The figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides a general introduction to the concept of bispecific antibodies, covering basics such as antibody technology, the conventional monoclonal antibody and its comparison with bispecific antibody. The chapter also highlights the historic evolution of the industry since the launch of first anti-CD3 antibody, Orthoclone Okt3, in 1986.

Chapter 3  provides a detailed overview and background of the bispecific antibodies market. This chapter covers a detailed pipeline analysis of various molecules under preclinical and clinical trials. We have segmented the drugs on the basis of respective technologies and indications.

Chapter 4  analyses the commercial potential of the global bispecific antibody market, with a special emphasis on the future growth over the next ten years. The market forecast is based on the evolution of the current marketed drug (Removab) and the likely adoption of various drugs which are in advanced clinical trial stages.

Chapter 5  focuses on the various technology platforms currently available or being developed for bispecific antibody production. The chaper highlights many companies which are active in the bispecific antibody market either as drug developers and / or technology providers. We have profiled, in detail, the most promising technologies which form the basis of upcoming pipeline drugs. In addition, this chapter also provides details on the recent partnerships which have emerged in this field.

Chapter 6  provides profiles of the key companies in the bispecific antibody market. Each company profile includes information such as financial performance, geographical presence, marketed / pipeline drugs and recent developments.

Chapter 7  analyses the various factors impacting the global bispecific antibody market under the SWOT framework. We examine the various technological, commercial and regulatory trends which have shaped the industry till date.

Chapter 8  concludes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 9  is the appendix, which lists all the companies and organisations mentioned in this report.

Chapter 10  is the appendix, which provides tabulated data and numbers for all the figures provided in the report.

Table of Contents

1. EXECUTIVE SUMMARY
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
1.4. Key Highlights
1.4.1. Removab is the Only Approved and Marketed Bispecific Antibody
1.4.2. Bispecific Antibodies are being Developed for Both Oncological and Non-oncological Indications
1.4.3. Big Pharma and Small Pharma are Equally Involved in the Market
1.4.4. Future Market Potential
1.4.5. BiTE and Triomab Technologies are the Backbone of Most Pipeline Drugs
1.4.6. Strengths Overcome Weaknesses

2. INTRODUCTION
2.1. Chapter Overview
2.2. Immunotherapy: Antibody Ammunitions
2.3. Antibody Based Therapeutics
2.3.1. Ten of the Approved Antibody Based Therapeutics are Non-Canonical
2.3.2. Dominance of Antibody Based Therapeutics
2.4. Structure of an Antibody
2.5. Monoclonal Antibodies v/s. Bispecific Antibodies
2.5.1. Monoclonal Antibodies
2.5.2. Bispecific Monoclonal Antibody
2.5.3. The Bispecific Advantage
2.6. Bispecific Antibody Formats
2.7. Evolution Of Bispecific Antibodies
2.7.1. First Generation Bispecific Antibodies
2.7.1.1. Triomabs: Made Using Hybridomas / Quadromas
2.7.1.2. Shortcoming of First Generation Bispecific Antibodies
2.7.2. Second Generation Bispecific Antibodies
2.7.2.1. Tandem Single-chain Variable Fragment (scFv)
2.7.2.2. Diabodies
2.7.2.3. Two-in-one antibody
2.7.2.4. Dual Variable Domain Antibodies (DVD-Ig)
2.7.2.5. Shortcoming Of Recombinant Bispecific Antibodies
2.8. Types Of Bispecific Antibodies by Mode of Action
2.8.1. T Cell Engagement
2.8.2. Pre-targeting Systems
2.8.3. Ligand Neutralisation And Cross Linking Of Receptors System
2.9. Companies Active In The Market

3. MARKET OVERVIEW AND PIPELINE OF BISPECIFIC ANTIBODIES
3.1. Introduction
3.2. Drugs Indicated for Oncological Diseases
3.3. Drugs Indicated For Non-Oncological Diseases
3.4. Drugs In Preclinical Trials
3.5. Analysis of the Pipeline
3.5.1. Drugs Are Spread In Phase I And Phase II Of Clinical Trials
3.5.2. Most Drugs Deploy Use of the T Engager Cell Mechanism Using CD3 Antigen Recognition
3.5.3. Pipeline Dominated by Drugs Indicated for Oncological Diseases
3.5.3.1. Focus on Solid Tumor
3.5.4. Companies With the Most Active Pipeline
 
4. CURRENT MARKET AND FORECAST
4.1. Introduction
4.1.1. Scope and Limitations
4.1.2. Assumptions For Market Forecast
4.2. Overall Bispecific Antibodies Market
4.2.1. Overall Bispecific Antibodies Market Forecast: Short-Midterm, 2013 - 2018
4.2.2. Overall Bispecific Antibodies Market Forecast: Long Term, 2018 - 2023
4.3. Catumaxomab / Removab (Fresenius Biotech, Trion Pharma, Neopharm)
4.3.1. Drug Overview
4.3.2. Removab: Structure and Mechanism of action
4.3.3. Orphan Drug Designations for Removab
4.3.4. Geographical Presence
4.3.5. Cost of Removab
4.3.6. Current Status of Development
4.3.7. Removab Sales (2011 - Q1 2013)
4.3.8. Reimbursement for Removab
4.3.9. Market Opportunity In Cancer Associated Malignant Ascites
4.3.10. Catumaxomab / Removab Sales Forecast: Short-Mid Term, 2013 - 2018
4.3.11. Catumaxomab / Removab Sales Forecast: Long Term, 2018 - 2023
4.4. Duligotumab / MEHD7945A / RG7597 (Roche / Genentech)
4.4.1. Overview
4.4.2. Structure and Mechanism of Action
4.4.3. Current Status of Development
4.4.4. Competition for Duligotumab
4.4.5. Duligotumab / MEHD7945A / RG7597 Sales Forecast: Long Term, 2018 - 2023
4.5. PF-04382923 / RN6G (Pfizer)
4.5.1. Overview
4.5.2. Mechanism of Action
4.5.3. Current Status of Development
4.5.4. Dry AMD: An Attractive Opportunity
4.5.5. PF-04382923 / RN6G Sales Forecast: Long Term, 2018 - 2023
4.6. SAR156597 (Sanofi)
4.6.1. Drug Specifications
4.6.2. Mechanism of Action
4.6.3. Orphan Drug Status
4.6.4. Idiopathic Pulmonary Fibrosis: An Attractive Opportunity
4.6.5. Current Status of Development
4.6.6. SAR156597 Sales Forecast: Short-Mid Term, 2013 - 2018
4.6.7. SAR156597 Sales Forecast: Long Term, 2018 - 2023
4.7. Ozoralizumab / ATN 103 (Ablynx)
4.7.1. Drug Specifications
4.7.2. Mechanism of Action
4.7.3. Highs and Lows of Development
4.7.4. Competition for Ozoralizumab
4.7.5. Current Ongoing Trials
4.7.6. Ozoralizumab / ATN 103 Sales Forecast: Long Term, 2018 - 2023
4.8. ALX-0061 (Ablynx)
4.8.1. Drug Specifications
4.8.2. Mechanism of Action
4.8.3. Desirable Features of ALX-0061
4.8.4. Current Status of Development
4.8.5. Competiton for ALX-0061
4.8.6. ALX-0061 Sales Forecast: Long Term, 2018 - 2023
4.9. MM-111 (Merrimack Pharmaceuticals)
4.9.1.1. Drug Specifications
4.9.1.2. Mechanism of Action
4.9.2. Recent Developments
4.9.2.1. Current Development Status
4.9.3. Potential in Patients With Moderate Her2 Expression
4.9.4. MM-111 Sales Forecast: Long Term, 2018 - 2023
4.10. Blinatumomab / MT 103 / MEDI 538 / AMG 103 (AMGEN)
4.10.1. Drug Specifications
4.10.2. Mechanism of Action
4.10.3. Amgen's Addition To Its Pipeline
4.10.4. Orphan Drug Designation
4.10.5. Current Development Status
4.10.6. Competitor Drugs
4.10.7. Blinatumomab / MT 103 / MEDI 538 / AMG 103 Sales Forecast: Short-Mid Term, 2013 - 2018
4.10.8. Blinatumomab / MT 103 / MEDI 538 / AMG 103 Sales Forecast: Long Term, 2018 - 2023
4.11. OTHER PIPELINE DRUGS
4.11.1. CD20Bi / FBT-A05 / Lymphomun (Fresenius Biotech) investigator-sponsored trials
4.11.1.1. Drug Specifications and Mechanism of action
4.11.1.2. Current Development Status
4.11.2. TF2 (Immunomedics)  pretargeting imaging and radioimmunotherapy agent
4.11.2.1. Drug Specifications
4.11.2.2. Mechanism of action
4.11.2.3. Current Development Status
4.11.3. Ertumaxomab/Rexomun (Fresenius Biotech) phase 2 terminated
4.11.3.1. Drug Specifications
4.11.3.2. Current Development Status
 
5. TECHNOLOGY PLATFORMS
5.1. Introduction
5.2. Bispecific Antibody Production: Technology Providers And Available Technologies
5.3. Promising Technologies
5.3.1. Triomab / Quadroma (Trion Pharma)
5.3.1.1. The Technology
5.3.1.2. Drugs Based On Triomab
5.3.1.3. Pharmaceutical Companies Showing Interest in the Technology
5.3.2. Tribody technology (Biotecnol)
5.3.2.1. The Technology
5.3.2.2. Drugs Based On Tribody
5.3.2.3. Pharmaceutical Companies Showing Interest In The Technology
5.3.2.4. Advantages Of Tribody Technology
5.3.3. Bispecific T Cell Engager / BiTE (Amgen)
5.3.3.1. The Technology
5.3.3.2. Drugs Based on BiTE
5.3.3.3. Pharmaceutical Companies Showing Interest in the Technology
5.3.3.4. Advantages Of BiTE Technology
5.3.4. DART (MacroGenics)
5.3.4.1. The Technology
5.3.4.2. Drugs Based On DART
5.3.4.3. Pharmaceutical Companies Showing Interest In The Technology
5.3.4.4. Advantages of DART
5.3.5. DuoBody (Genmab)
5.3.5.1. The Technology
5.3.5.2. Pharmaceutical Companies Showing Interest In The Technology
5.3.5.3. Advantages Of DuoBody Technology
5.3.6. TandAb (Affimed)
5.3.6.1. The Technology
5.3.6.2. Mode of Action
5.3.6.3. Drugs Based on TandAb
5.3.6.4. Advantages Of TandAb Technology
5.3.7. DVD-Ig (AbbVie)
5.3.7.1. The Technology
5.3.7.2. Drugs Based on DVD-Ig
5.3.7.3. Advantages Of DVD-Ig Technology
5.3.8. Nanobody (Ablynx)
5.3.8.1. The Technology
5.3.8.2. Drugs Based On Nanobody
5.3.8.3. Pharmaceutical Companies Showing Interest In The Technology
5.3.8.4. Advantages of Nanobody
5.3.9. CrossMab Technology (Roche)
5.3.9.1. The Technology
5.3.9.2. Drugs Based On CrossMab
5.3.9.3. Advantages Of CrossMab
5.3.10. Dock and Lock (Immunomedics)
5.3.10.1. The Technology
5.3.10.2. Drugs Based on DNL
5.3.10.3. Advantages Of DNL Technology
5.4. Screening and Purification Technology Companies
5.5. Pharmaceutical Company Business Models
5.5.1. Partnership / Licensing Model
5.5.2. Acquisition Model
5.5.3. In-house Model
5.6. Other Upcoming Companies and Respective Technologies
5.6.1. Paktis Antibody Services GmbH
5.6.2. Fabion Pharmaceuticals
5.6.3. Numab
5.6.4. Synimmune
5.6.5. Ambrx
5.6.6. Merus
5.7. Recent Partnerships
 
6. PROFILES OF LEADING COMPANIES
6.1. Amgen
6.1.1. Geographical Presence
6.1.2. Financial Performance
6.1.3. Technology and Pipeline Drugs
6.1.3.1. BiTE: The Proprietary Technology
6.1.3.2. Pipeline Drugs
6.2. Fresenius Biotech (now a part of Neopharm)
6.2.1. Geographical Presence
6.2.2. Financial Performance
6.2.3. Marketed and Pipeline Drugs
6.2.3.1. Removab: The Only Marketed Bispecific Antibody
6.2.3.2. Ertumaxomab
6.2.3.3. FBT-A05
6.2.4. Sale of Fresenius Biotech
6.3. Merrimack Pharmaceuticals
6.3.1. Financial Performance
6.3.2. Pipeline Drugs
6.3.2.1. MM-111
6.3.2.2. MM-141
6.4. Affimed
6.4.1. Financial Information
6.4.2. Technology and Pipeline Drugs
6.4.2.1. TandAb technology
6.4.3. Pipeline Drugs
6.5. Merus
6.5.1. Financial Information
6.5.2. Technology and Pipeline Products
6.5.2.1. Biclonics: The Proprietary Technology
6.5.2.2. Pipeline Drugs
6.6. AbbVie
6.6.1. Geographical Presence
6.6.2. Financial Performance
6.6.3. Technology and Pipeline Drugs
6.6.3.1. DVD-Ig: The Proprietary Technology
6.6.3.2. Pipeline Drugs
 
7. SWOT ANALYSIS
7.1. Overview
7.2. Strengths
7.3. Weaknesses
7.4. Opportunities
7.5. Threats
 
8. CONCLUSIONS
8.1. A Budding Market Ready to Bloom
8.2. Improvements in Purification Systems of Bispecific Antibodies is Critical
8.3. Key Driving Factors
8.4. Concluding Remarks
 
9. LIST OF COMPANIES AND ORGANISATIONS
 
10. TABLES

List of Figures

Figure 2.1 Number of Approved non-Canonical Antibody Based Therapeutics
Figure 2.2 Sales of Top 10 Drugs (USD MM), 2012
Figure 2.3 Parts of an Antibody
Figure 3.1 Pipeline Drugs: By Phase of Development
Figure 3.2 Pipeline Drugs: By Type of Bispecific System
Figure 3.3 Pipeline Drugs: By Indication
Figure 3.4 Oncology Bispecific Drugs: By Types of Cancer
Figure 4.1 Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2013 - 2018 (Base Scenario)
Figure 4.2 Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 4.3 Removab Quarterly Sales, 2011-2013 (EUR MM)
Figure 4.4 Malignant Ascites Market Share (%) – by Type of Cancer
Figure 4.5 Catumaxomab / Removab Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)
Figure 4.6 Catumaxomab / Removab Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 4.7 Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 4.8 Lucentis Sales (USD MM), 2006-2012
Figure 4.9 PF-0438293 / RN6G Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 4.10 SAR156597 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)
Figure 4.11 SAR156597 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 4.12 Anti-rheumatics Drug Market, 2012 - by Leading Drugs (USD MM, %)
Figure 4.13 Ozoralizumab / ATN 103 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 4.14 ALX-0061 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 4.15 MM-111 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 4.16 Blinatumomab / MT 103 / MEDI 538 / AMG 103, Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)
Figure 4.17 Blinatumomab / MT 103 / MEDI 538 / AMG 103 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 5.1 Business Models for Bispecific Antibody Therapeutic Development
Figure 6.1 Fresenius Group: Distribution of Sales, 2012
Figure 8.1 Bispecific Antibodies Market Forecast (USD MM): 2016, 2019, 2023

List of Tables

Table 2.1 Approved Antibody Based Therapeutics
Table 3.1 Oncological Bispecific Antibodies in Clinical Trials
Table 3.2 Non- Oncological Bispecific Antibodies in Clinical Trials
Table 3.3 Bispecific Antibodies in Preclinical Trials
Table 4.1 Bispecific Antibodies in Clinical Development (Phase II and Higher): Current Development Phase and Expected Launch Year
Table 4.2 Orphan Drug Designations for Removab
Table 4.3 Removab: Treatment Schedule and Cost
Table 4.4 Removab: Ongoing Clinical Trials
Table 4.5 Duligotumab / MEHD7945A / RG7597: Ongoing Clinical Trials
Table 4.6 Duligotumab / MEHD7945A / RG7597: Competitor Drug Analysis
Table 4.7 PF-04382923: Ongoing Clinical Trials
Table 4.8 Advanced Dry AMD: Some Drugs Under Development, 2013
Table 4.9 Some Drugs Under Development for Idiopathic Pulmonary Fibrosis, 2013
Table 4.10 SAR156597: Ongoing Clinical Trials
Table 4.11 Ozoralizumab / ATN 103: Ongoing Clinical Trials
Table 4.12 ALX-0061: Ongoing Clinical Trials
Table 4.13 ALX-0061: Competition Drug Analysis
Table 4.14 MM-111: Ongoing Clinical Trials
Table 4.15 Orphan Drug Designations for Blinatumomab
Table 4.16 Blinatumomab / MT 103 / MEDI 538 / AMG 103: Ongoing Clinical Trials
Table 4.17 Comparison of Blinatumomab / MT 103 / MEDI 538 / AMG 103 and SAR3419
Table 4.18 CDBi20: Ongoing Clinical Trials
Table 4.19 TF2: Ongoing Clinical Trials
Table 4.20 Rexomun: Ongoing Clinical Trials
Table 5.1 Companies Active in Bispecific Antibody Space
Table 5.2 Bispecific Antibody Technologies Platforms
Table 5.3 Drugs based on Triomab Technology
Table 5.4 Drugs based on Tribody Technology
Table 5.5 Drugs based on BiTE Technology
Table 5.6 Agreement / Partnership for BiTE Platform
Table 5.7 Drugs Based on DART
Table 5.8 Agreement / Partnership for DuoBody Platform
Table 5.9 Drugs Based on TandAb Technology
Table 5.10 Drugs Based on DVD-Ig Technology
Table 5.11 Drugs Based on Nanobody Technology
Table 5.12 Drugs Based on CrossMabTechnology
Table 5.13 Drugs Based on Dock and Lock Technology
Table 5.14 Bispecific Antibody Development: Recent Partnerships
Table 6.1 Amgen: Pipeline of Bispecific Antibodies (Phase 1 and above)
Table 6.2 Fresenius: Pipeline of Bispecific Antibodies (Phase 1 and Above)
Table 6.3 Merrimack Pharmaceuticals: Pipeline of Bispecific Antibodies (Phase 1 and Above)
Table 6.4 Affimed: Pipeline of Bispecific Antibodies
Table 6.5 Merus: Pipeline of Bispecific Antibodies
Table 6.6 Abbvie: Pipeline of Bispecific Antibodies (Phase 1 and Above)
Table 7.1 SWOT Analysis of the Bispecific Antibodies Market
Table 7.2 Contract Manufacturing Organisations with Bispecific Antibody Capabilities – Screening, Expression or Purification
Table 7.3 Companies Working to Develop IgG/Non-IgG Fusion Therapeutics
Table 10.1Approved non-Canonical Antibody Based Therapeutics
Table 10.2 Sales (USD) of top 10 drugs, 2012
Table 10.3 Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2013 - 2018 (Base Scenario)
Table 10.4 Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2013 - 2018 (Conservative Scenario)
Table 10.5 Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2013 - 2018 (Optimistic Scenario)
Table 10.6 Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.7 Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.8 Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2018 - 2023 (Optimistic Scenario)
Table 10.9 Catumaxomab / Removab Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)
Table 10.10 Catumaxomab / Removab Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Conservative Scenario)
Table 10.11 Catumaxomab / Removab Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Optimistic Scenario)
Table 10.12 Catumaxomab / Removab Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.13 Catumaxomab / Removab Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.14 Catumaxomab / Removab Market (USD MM), Long Term Forecast: 2018 - 2023 (Optimistic Scenario)
Table 10.15 Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.16 Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.17 Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2018 - 2023 (Optimistic Scenario)
Table 10.18 PF-0438293 / RN6G Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.19 PF-0438293 / RN6G Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.20 PF-0438293 / RN6G Market (USD MM), Long Term Forecast: 2018 - 2023 (Optimistic Scenario)
Table 10.21 SAR156597 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)
Table 10.22 SAR156597 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Conservative Scenario)
Table 10.23 SAR156597 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Optimistic Scenario)
Table 10.24 SAR156597 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.25 SAR156597 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.26 SAR156597 Market (USD MM), Long Term Forecast: 2018 - 2023 (Optimistic Scenario)
Table 10.27 Ozoralizumab / ATN 103 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.28 Ozoralizumab / ATN 103 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.29 Ozoralizumab / ATN 103 Market (USD MM), Long Term Forecast: 2018 - 2023 (Optimistic Scenario)
Table 10.30 ALX-0061 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.31 ALX-0061 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.32 ALX-0061 Market (USD MM), Long Term Forecast: 2018 - 2023 (Optimistic Scenario)
Table 10.33 MM-111 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.34 MM-111 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.35 MM-111 Market (USD MM), Long Term Forecast: 2018 - 2023 (Optimistic Scenario)
Table 10.36 Blinatumomab / MT 103 / MEDI 538 / AMG 103, Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)
Table 10.37 Blinatumomab / MT 103 / MEDI 538 / AMG 103, Short-Mid Term Forecast: 2013 - 2018 (Conservative Scenario)
Table 10.38 Blinatumomab / MT 103 / MEDI 538 / AMG 103, Short-Mid Term Forecast: 2013 - 2018 (Optimistic Scenario)
Table 10.39 Blinatumomab / MT 103 / MEDI 538 / AMG 103, Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.40 Blinatumomab / MT 103 / MEDI 538 / AMG 103, Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.41 Blinatumomab / MT 103 / MEDI 538 / AMG 103, Long Term Forecast: 2018 - 2023 (Optimistic Scenario)

Listed Companies

The following companies have been mentioned in the report.

  1. Abbvie
  2. Ablynx
  3. Active Biotech
  4. Acucela
  5. Adimab
  6. Affimed
  7. Allergan
  8. Allozyne
  9. Ambrx
  10. Amgen
  11. Amphivena Therapeutics Inc
  12. Baliopharm
  13. Bayer
  14. Beijing ABT Genetic Engineering Technology Co.
  15. Bicycle Therapeutics
  16. Biogen Idec
  17. Biotecnol
  18. BMS
  19. Boehringer Ingelheim
  20. Celgene
  21. Chiome Bioscience
  22. Chromacon
  23. Chugai
  24. Covagen
  25. Dow Pharma
  26. Dutalys
  27. Eli Lilly
  28. EMD Serono
  29. Emergent
  30. Epigen Biotech
  31. Fabion Pharmaceuticals
  32. FibroGen
  33. Fresenius Biotech
  34. F-Star
  35. GeneNtech
  36. Genmab
  37. Gilead Biosciences
  38. Goodwin Biotechnology
  39. GSK
  40. Imclone Systems
  41. ImmunGene
  42. Immunocore
  43. Immunomedics
  44. Intermune
  45. Janssen
  46. KBI Biopharma
  47. Kyowa Hakko Kirin
  48. Lindis Biotech
  49. Macrogenics
  50. Medarex
  51. MedImmune
  52. Merck
  53. Meridian Life Science
  54. Merrimack Pharmaceuticals
  55. Merus
  56. Micromet
  57. Mitsubishi Tanabe
  58. Molecular Partners AG
  59. Novartis
  60. Novimmune
  61. Numab
  62. OcellO
  63. Oncomed
  64. OtSuka Pharma
  65. Paktis Antibody Services GmbH
  66. Pfizer
  67. PharmAbcine
  68. Philogen
  69. Polytherics
  70. Receptorlogic
  71. Regeneron
  72. Roche
  73. Sanofi
  74. Santen
  75. Servier
  76. Shanghai Genomics
  77. Shionogi & Co
  78. Sutro Biopharma
  79. Symphogen
  80. Synimmune
  81. Tanabe Research Labs
  82. Trion
  83. UCB-Celltech
  84. X-Body Biosciences
  85. Xencor
  86. Zymeworks
  87. Zymogenetics
  88. Zyngenia

The following organisations have been mentioned in the report:

  1. Australian Therapeutic Goods Administration
  2. Barbara Ann Karmanos Cancer Institute
  3. Centre René Gauducheau
  4. EMA
  5. FDA
  6. French National Centre for Scientific Research
  7. Institut National De La Santé Et De La Recherche Médicale
  8. Nantes University Hospital
  9. National Cancer Institute
  10. Radboud University
  11. Roger Williams Medical Centre
  12. Scott and White Hospital
  13. Technische Universität München
  14. Université de Toulouse
  15. University Hospital, Tuebingen

PRICING DETAILS

USD 1,699

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.